Moreover, the Capsugel, a global leader in delivering high quality, innovative dosage forms to the healthcare industry, launches the new drug delivery system as per the commitment to innovate for their costumer. For instance, in October 2015, Capsugel announced the global commercial launch of its enTRinsic drug delivery technology, providing full enteric protection and targeted release of gastric acid and heat sensitive active ingredients to the upper gastrointestinal tract.
Furthermore, in April 2019, Aquestive Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application (NDA) for their investigational product, Riluzole oral film (ROF), which the company intends to market under the brand name, Exservan. ROF is used for treatment of amyotrophic lateral sclerosis (ALS). ROF is delivered through a postage stamp sized film which dissolves in the mouth. The FDA had designated orphan drug status to the drug in January 2018.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients